Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
new option listings on November 25th » 08:30
11/25/20
11/25
08:30
11/25/20
08:30
ABIO

ARCA Biopharma

$4.04 /

-0.11 (-2.65%)

, AHCO

AdaptHealth

$28.87 /

-0.4 (-1.37%)

, DMTK

DermTech

$11.65 /

-0.3 (-2.51%)

, DRIV

Digital River

$22.11 /

+0.495 (+2.29%)

, EDOC

Applied Voice Recognition Inc

$17.82 /

-0.17 (-0.94%)

, EKSO

Ekso Bionics

$5.80 /

+0.56 (+10.69%)

, FAN

First Trust Global Wind Energy

$20.38 /

+0.06 (+0.30%)

, GP

GreenPower Motor

$25.60 /

-2.25 (-8.08%)

, KZIA

Kazia Therapeutics

$10.17 /

+0.62 (+6.49%)

, MSP

Datto

$25.97 /

-1.02 (-3.78%)

, QLGN

Qualigen Therapeutics

$3.31 /

-0.04 (-1.19%)

, ROOT

Root

$16.71 /

-0.335 (-1.97%)

, RVMD

Revolution Medicines

$41.58 /

+0.895 (+2.20%)

, TCON

Tracon Pharmaceuticals

$8.45 /

-0.55 (-6.11%)

New option listings for…

New option listings for November 25th include ARCA Biopharma (ABIO), AdaptHealth Corporation (Class A Stock) (AHCO), DermTech Inc (DMTK), Global X Autonomous and Electric Vehicles (DRIV), Direxion Daily Industrials Bull 3x Shares (DUSL), Global X E commerce ETF (EBIZ), Global X Telemedicine and Digital Health (EDOC), Ekso Bionics (EKSO), First Trust ISE Global Wind Energy Index Fund (FAN), Fidelity Low Volatility Factor ETF (FDLO), First Trust DJ Global Select Dividend Index Fund (FGD), GreenPower Motor Company Inc (GP), Direxion Daily South Korea Bull 3X Shares (KORU), Kazia Therapeutics Ltd (ADS) (KZIA), Datto Holding Corp (MSP), Qualigen Therapeutics Inc (QLGN), Root Inc (ROOT), Revolution Medicines Inc (RVMD), TRACON Pharmaceuticals (TCON), Direxion Daily Transportation Bull 3x Shares (TPOR), and WisdomTree Cloud Computing Fund (WCLD).

ShowHide Related Items >><<
TCON Tracon Pharmaceuticals
$8.45 /

-0.55 (-6.11%)

RVMD Revolution Medicines
$41.58 /

+0.895 (+2.20%)

ROOT Root
$16.71 /

-0.335 (-1.97%)

QLGN Qualigen Therapeutics
$3.31 /

-0.04 (-1.19%)

MSP Datto
$25.97 /

-1.02 (-3.78%)

KZIA Kazia Therapeutics
$10.17 /

+0.62 (+6.49%)

GP GreenPower Motor
$25.60 /

-2.25 (-8.08%)

EKSO Ekso Bionics
$5.80 /

+0.56 (+10.69%)

DMTK DermTech
$11.65 /

-0.3 (-2.51%)

AHCO AdaptHealth
$28.87 /

-0.4 (-1.37%)

ABIO ARCA Biopharma
$4.04 /

-0.11 (-2.65%)

ABIO ARCA Biopharma
$4.04 /

-0.11 (-2.65%)

AHCO AdaptHealth
$28.87 /

-0.4 (-1.37%)

11/17/20 Deutsche Bank
AdaptHealth price target raised to $36 from $26 at Deutsche Bank
11/16/20 Baird
AdaptHealth initiated with an Outperform at Baird
11/05/20 SVB Leerink
AdaptHealth price target raised to $32.50 from $23.50 at SVB Leerink
08/11/20 RBC Capital
AdaptHealth price target raised to $33 from $24 at RBC Capital
DMTK DermTech
$11.65 /

-0.3 (-2.51%)

10/29/20 William Blair
DermTech initiated with an Outperform at William Blair
09/11/20
Fly Intel: Top five analyst initiations
09/10/20 Brookline
DermTech initiated with a Buy at Brookline
09/10/20 Cowen
DermTech initiated with an Outperform at Cowen
DRIV Digital River
$22.11 /

+0.495 (+2.29%)

EDOC Applied Voice Recognition Inc
$17.82 /

-0.17 (-0.94%)

EKSO Ekso Bionics
$5.80 /

+0.56 (+10.69%)

06/26/20 H.C. Wainwright
Ekso Bionics price target raised to $12 from $8 at H.C. Wainwright
01/10/20 H.C. Wainwright
Ekso's Q4 pre-announcement 'bodes well' for 2020 growth, says H.C. Wainwright
FAN First Trust Global Wind Energy
$20.38 /

+0.06 (+0.30%)

GP GreenPower Motor
$25.60 /

-2.25 (-8.08%)

11/25/20 Maxim
GreenPower Motor price target raised to $35 from $22 at Maxim
11/19/20 BTIG
BTIG reiterates Buy rating on GreenPower Motor after investors meetings
11/02/20
Fly Intel: Top five analyst initiations
11/02/20 Maxim
GreenPower Motor initiated with a Buy at Maxim
KZIA Kazia Therapeutics
$10.17 /

+0.62 (+6.49%)

MSP Datto
$25.97 /

-1.02 (-3.78%)

11/17/20 Citi
Datto initiated with a Neutral at Citi
11/16/20 William Blair
Datto initiated with an Outperform at William Blair
11/16/20 Mizuho
Datto initiated with a Neutral at Mizuho
11/16/20 Morgan Stanley
Datto initiated with an Equal Weight at Morgan Stanley
QLGN Qualigen Therapeutics
$3.31 /

-0.04 (-1.19%)

08/25/20 Alliance Global Partners
Qualigen upgraded to Buy from Neutral at Alliance Global Partners
ROOT Root
$16.71 /

-0.335 (-1.97%)

11/23/20 Barclays
Root initiated with an Equal Weight at Barclays
11/23/20 Truist
Root initiated with a Buy at Truist
11/23/20 Cantor Fitzgerald
Root initiated with an Overweight at Cantor Fitzgerald
11/23/20 UBS
Root initiated with a Neutral at UBS
RVMD Revolution Medicines
$41.58 /

+0.895 (+2.20%)

10/26/20 H.C. Wainwright
Revolution Medicines price target raised to $54 from $52 at H.C. Wainwright
09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
05/21/20
Fly Intel: Top five analyst initiations
05/21/20 H.C. Wainwright
Revolution Medicines initiated with a Buy at H.C. Wainwright
TCON Tracon Pharmaceuticals
$8.45 /

-0.55 (-6.11%)

09/17/20 H.C. Wainwright
Tracon Pharmaceuticals price target raised to $7 from $4 at H.C. Wainwright
04/24/20 H.C. Wainwright
Tracon Pharmaceuticals price target lowered to $4 from $6 at H.C. Wainwright
03/10/20 H.C. Wainwright
Tracon Pharmaceuticals price target lowered to $6 from $13 at H.C. Wainwright
02/28/20 H.C. Wainwright
Tracon Pharmaceuticals price target lowered to $13 from $18 at H.C. Wainwright
TCON Tracon Pharmaceuticals
$8.45 /

-0.55 (-6.11%)

RVMD Revolution Medicines
$41.58 /

+0.895 (+2.20%)

QLGN Qualigen Therapeutics
$3.31 /

-0.04 (-1.19%)

MSP Datto
$25.97 /

-1.02 (-3.78%)

EKSO Ekso Bionics
$5.80 /

+0.56 (+10.69%)

DMTK DermTech
$11.65 /

-0.3 (-2.51%)

AHCO AdaptHealth
$28.87 /

-0.4 (-1.37%)

ABIO ARCA Biopharma
$4.04 /

-0.11 (-2.65%)

  • 28
    Oct
  • 21
    Oct
  • 03
    Sep
  • 09
    Jul
  • 01
    Jul
  • 13
    Feb
GP GreenPower Motor
$25.60 /

-2.25 (-8.08%)

RVMD Revolution Medicines
$41.58 /

+0.895 (+2.20%)

ROOT Root
$16.71 /

-0.335 (-1.97%)

MSP Datto
$25.97 /

-1.02 (-3.78%)

EKSO Ekso Bionics
$5.80 /

+0.56 (+10.69%)

Recommendations
Turning Point price target raised to $130 from $120 at Oppenheimer » 05:03
11/13/20
11/13
05:03
11/13/20
05:03
TPTX

Turning Point Therapeutics

$108.32 /

+3.68 (+3.52%)

Oppenheimer analyst…

Oppenheimer analyst Matthew Biegler raised the firm's price target on Turning Point Therapeutics to $130 from $120 and reiterates an Outperform rating on the shares following the company's Q3 results. The recent outperformance of Turning Point shares reflects investor enthusiasm for TPX-0022 and the company's macrocyclic discovery platform, which has now delivered "two potentially best-in-class TKIs for two very different targets," Biegler tells investors in a research note. He believes repotrectinib could receive accelerated approval by 2023.

ShowHide Related Items >><<
TPTX Turning Point Therapeutics
$108.32 /

+3.68 (+3.52%)

TPTX Turning Point Therapeutics
$108.32 /

+3.68 (+3.52%)

10/30/20 Roth Capital
Turning Point Therapeutics price target raised to $133 from $77 at Roth Capital
10/26/20 Wells Fargo
Turning Point Therapeutics price target raised to $133 from $88 at Wells Fargo
10/26/20 H.C. Wainwright
Turning Point Therapeutics price target raised to $130 from $100 at H.C. Wainwright
10/25/20 Oppenheimer
Turning Point Therapeutics price target raised to $120 from $90 at Oppenheimer
TPTX Turning Point Therapeutics
$108.32 /

+3.68 (+3.52%)

  • 27
    Oct
  • 19
    May
Earnings
Revolution Medicines reports Q3 EPS (42c), consensus (39c) » 07:33
11/12/20
11/12
07:33
11/12/20
07:33
RVMD

Revolution Medicines

$35.72 /

+0.705 (+2.01%)

Reports Q3 revenue…

Reports Q3 revenue $12.7M, consensus $14.24M. "Revolution Medicines is a leader in developing innovative medicines and treatment strategies on behalf of patients with RAS-addicted tumors. We are advancing a growing portfolio consisting of both direct RAS Inhibitors and RAS Companion Inhibitors designed to enable combination approaches, including RMC-4630 targeting SHP2, RMC-5552 targeting mTORC1, and inhibitors of SOS1," said Mark Goldsmith, CEO and chairman of Revolution Medicines. "In our RAS Companion Inhibitor portfolio, we continue to make important strides with RMC-4630, our clinical stage inhibitor of SHP2. We selected the recommended Phase 2 dose and schedule for both our monotherapy trial and the RMC-4630/cobimetinib combination arm of the RMC-4630-02 clinical trial, and each trial will further evaluate the appropriate RP2DS in expansion cohorts of molecularly selected patients. As anticipated, we recently dosed a first patient in a new combination study of RMC-4630 with the third-generation EGFR inhibitor, osimertinib. We also entered into a new clinical collaboration with AstraZeneca to study RMC-4630 in combination with an emerging asset targeting KRASG12C from AstraZeneca's portfolio. In addition, we accelerated growth of our RAS Inhibitor platform, which has produced a collection of potent, cell-active inhibitors of diverse oncogenic RAS variants responsible for the vast majority of RAS-addicted cancers. Previously, we demonstrated significant anti-tumor effects of a representative potent and oral inhibitor of KRASG12C. During the third quarter we confirmed the broad scope of our platform by demonstrating that representative KRASG12D inhibitors likewise induced tumor regressions in a preclinical model of human pancreatic cancer harboring the oncogenic KRASG12D mutation. We have advanced our KRASG12C/NRASG12C, KRASG12D, KRASG13C and KRASG12V inhibitor programs into lead optimization."

ShowHide Related Items >><<
RVMD Revolution Medicines
$35.72 /

+0.705 (+2.01%)

RVMD Revolution Medicines
$35.72 /

+0.705 (+2.01%)

10/26/20 H.C. Wainwright
Revolution Medicines price target raised to $54 from $52 at H.C. Wainwright
09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
05/21/20
Fly Intel: Top five analyst initiations
05/21/20 H.C. Wainwright
Revolution Medicines initiated with a Buy at H.C. Wainwright
RVMD Revolution Medicines
$35.72 /

+0.705 (+2.01%)

  • 09
    Jul
  • 13
    Feb
RVMD Revolution Medicines
$35.72 /

+0.705 (+2.01%)

Earnings
Cyclacel Pharmaceuticals reports Q3 EPS ($2.27), consensus (55c) » 16:12
11/11/20
11/11
16:12
11/11/20
16:12
CYCC

Cyclacel Pharmaceuticals

$3.50 /

+0.1 (+2.94%)

As of September 30, cash…

As of September 30, cash and cash equivalents totaled $23.1M, compared to $11.9M as of December 31, 2019. The increase of $11.2M was primarily due to net proceeds of $18.3M from an equity financing in April, offset by net cash used in operating activities of $6.8M. There were no revenues for each of the three months ended September 30, 2020 and 2019.. "We continue to execute on our clinical development plan for fadraciclib and CYC140 in both liquid and solid cancers," said Spiro Rombotis, president and CEO. "The recent ENA presentation highlighted fadraciclib's oral bioavailability and deepening confirmed response as a single agent. Recent publications elaborated the mechanistic rationale for fadraciclib highlighting dual inhibition of CDK2 and CDK9 cancer pathways. We are encouraged by evidence of antileukemic activity in our studies of fadraciclib in combination with venetoclax in hematological malignancies, including CLL. Dr. Mark Kirschbaum, our newly appointed CMO, is reviewing our programs and streamlining our clinical work flows to progress our clinical strategy and improve efficiency. We are looking forward to reporting data from ongoing studies and outlining our clinical development plans for fadraciclib and CYC140 to drive shareholder value."

ShowHide Related Items >><<
CYCC Cyclacel Pharmaceuticals
$3.50 /

+0.1 (+2.94%)

CYCC Cyclacel Pharmaceuticals
$3.50 /

+0.1 (+2.94%)

05/19/20 Brookline
Cyclacel Pharmaceuticals initiated with a Buy at Brookline
04/27/20
Fly Intel: Top five analyst initiations
04/27/20 Roth Capital
Cyclacel Pharmaceuticals assumed with a Buy at Roth Capital
CYCC Cyclacel Pharmaceuticals
$3.50 /

+0.1 (+2.94%)

Initiation
Syros Pharmaceuticals initiated with a Buy at Brookline » 07:52
11/10/20
11/10
07:52
11/10/20
07:52
SYRS

Syros Pharmaceuticals

$8.91 /

+0.4701 (+5.57%)

Brookline analyst Leah…

Brookline analyst Leah Rush Cann initiated coverage of Syros Pharmaceuticals with a Buy rating and $19 price target. Success in the next five years is "highly dependent" on the FDA approval and launch of SY-1425 in hematologic cancers, the analyst noted. She anticipates data for SY-1425, the company's lead compound, at the 2020 ASH Meeting, Rush Cann tells investors.

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$8.91 /

+0.4701 (+5.57%)

SYRS Syros Pharmaceuticals
$8.91 /

+0.4701 (+5.57%)

11/05/20 Roth Capital
Syros' SY-1425+Aza could be competitive in multiple settings, says Roth Capital
11/04/20
Fly Intel: Top five analyst upgrades
11/04/20 H.C. Wainwright
Syros Pharmaceuticals upgraded to Buy from Neutral at H.C. Wainwright
10/26/20 Roth Capital
Syros Pharmaceuticals price target raised to $20 from $17 at Roth Capital
SYRS Syros Pharmaceuticals
$8.91 /

+0.4701 (+5.57%)

Earnings
Syros Pharmaceuticals reports Q3 EPS (43c), consensus (38c) » 16:02
11/05/20
11/05
16:02
11/05/20
16:02
SYRS

Syros Pharmaceuticals

$8.20 /

-0.07 (-0.85%)

Reports Q3 revenue $3.8M,…

Reports Q3 revenue $3.8M, consensus $2.5M

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$8.20 /

-0.07 (-0.85%)

SYRS Syros Pharmaceuticals
$8.20 /

-0.07 (-0.85%)

11/05/20 Roth Capital
Syros' SY-1425+Aza could be competitive in multiple settings, says Roth Capital
11/04/20
Fly Intel: Top five analyst upgrades
11/04/20 H.C. Wainwright
Syros Pharmaceuticals upgraded to Buy from Neutral at H.C. Wainwright
10/26/20 Roth Capital
Syros Pharmaceuticals price target raised to $20 from $17 at Roth Capital
SYRS Syros Pharmaceuticals
$8.20 /

-0.07 (-0.85%)

Recommendations
Syros' SY-1425+Aza could be competitive in multiple settings, says Roth Capital » 11:09
11/05/20
11/05
11:09
11/05/20
11:09
SYRS

Syros Pharmaceuticals

$7.99 /

-0.28 (-3.39%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah noted that Syros Pharmaceuticals announced abstracts for two oral presentations at the American Society of Hematology, or ASH, annual meeting that will showcase the efficacy of SY-1425 in combination with azacitidine in newly diagnosed and relapsed/recurring AML patients. The "impressive" 61% CR/CRi rate in new diagnosis patients held steady with what was previously reported, and the 15% CRi rate in r/r patients was "very encouraging," said Jallah, who believes that the combo could be competitive in both settings. The analyst, who said she "eagerly awaits additional updates at ASH," has a Buy rating and $20 price target on Syros shares.

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$7.99 /

-0.28 (-3.39%)

SYRS Syros Pharmaceuticals
$7.99 /

-0.28 (-3.39%)

11/04/20
Fly Intel: Top five analyst upgrades
11/04/20 H.C. Wainwright
Syros Pharmaceuticals upgraded to Buy from Neutral at H.C. Wainwright
10/26/20 Roth Capital
Syros Pharmaceuticals price target raised to $20 from $17 at Roth Capital
09/22/20 Alliance Global Partners
Syros Pharmaceuticals initiated with a Buy at Alliance Global Partners
SYRS Syros Pharmaceuticals
$7.99 /

-0.28 (-3.39%)

Conference/Events
Syros Pharmaceuticals management to meet virtually with JMP Securities » 04:55
11/05/20
11/05
04:55
11/05/20
04:55
SYRS

Syros Pharmaceuticals

$8.29 /

+0.72 (+9.51%)

Virtual Meeting to be…

Virtual Meeting to be held on November 6 hosted by JMP Securities.

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$8.29 /

+0.72 (+9.51%)

SYRS Syros Pharmaceuticals
$8.29 /

+0.72 (+9.51%)

11/04/20
Fly Intel: Top five analyst upgrades
11/04/20 H.C. Wainwright
Syros Pharmaceuticals upgraded to Buy from Neutral at H.C. Wainwright
10/26/20 Roth Capital
Syros Pharmaceuticals price target raised to $20 from $17 at Roth Capital
09/22/20 Alliance Global Partners
Syros Pharmaceuticals initiated with a Buy at Alliance Global Partners
SYRS Syros Pharmaceuticals
$8.29 /

+0.72 (+9.51%)

Hot Stocks
Syros to present new data from Phase 2 SY-1425 trial at ASH meeting » 10:18
11/04/20
11/04
10:18
11/04/20
10:18
SYRS

Syros Pharmaceuticals

$8.45 /

+0.88 (+11.62%)

Syros Pharmaceuticals…

Syros Pharmaceuticals announced that it will present new clinical data from its fully enrolled, ongoing Phase 2 trial of SY-1425, its first-in-class oral selective retinoic acid receptor alpha agonist, at the 62nd American Society of Hematology Annual Meeting, taking place virtually December 5-8, 2020. The oral presentations will include data on SY-1425 in combination with azacitidine from a cohort of RARA-positive patients with relapsed or refractory acute myeloid leukemia and mature data on the combination in newly diagnosed unfit AML patients who are not suitable candidates for standard chemotherapy. In a separate poster presentation, Syros will present new data showing that the majority of RARA-positive patients have a disease phenotype associated with resistance to upfront treatment with venetoclax, further underscoring the potential of SY-1425 in combination to address an ongoing unmet need in newly diagnosed unfit AML patients.

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$8.45 /

+0.88 (+11.62%)

SYRS Syros Pharmaceuticals
$8.45 /

+0.88 (+11.62%)

11/04/20
Fly Intel: Top five analyst upgrades
11/04/20 H.C. Wainwright
Syros Pharmaceuticals upgraded to Buy from Neutral at H.C. Wainwright
10/26/20 Roth Capital
Syros Pharmaceuticals price target raised to $20 from $17 at Roth Capital
09/22/20 Alliance Global Partners
Syros Pharmaceuticals initiated with a Buy at Alliance Global Partners
SYRS Syros Pharmaceuticals
$8.45 /

+0.88 (+11.62%)

Upgrade
Fly Intel: Top five analyst upgrades » 09:54
11/04/20
11/04
09:54
11/04/20
09:54
AMD

AMD

$79.65 /

+3.07 (+4.01%)

, SPR

Spirit AeroSystems

$19.69 /

-0.16 (-0.81%)

, AMZN

Amazon.com

$3,183.43 /

+135.05 (+4.43%)

, BIDU

Baidu

$137.79 /

+3.84 (+2.87%)

, SYRS

Syros Pharmaceuticals

$8.42 /

+0.85 (+11.23%)

Catch up on today's…

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AMD (AMD) upgraded to Conviction Buy from Neutral at Goldman Sachs with analyst Toshiya Hari saying the 17% pullback in the stock since the September highs presents a "compelling opportunity" to participate in AMD's "multi-year share gain and margin expansion story." 2. Spirit AeroSystems (SPR) upgraded to Outperform from Market Perform at Cowen with analyst Cai von Rumohr saying Boeing's (BA) MAX is Spirit's largest and most profitable program, and its certification and initial deliveries appear likely by year-end. 3. Amazon.com (AMZN) upgraded to Buy from Hold at China Renaissance with analyst Ella Ji saying with its "industry-leading" user engagement, supply chain and logistics capacity, Amazon remains the best positioned e-commerce stock. 4. Baidu (BIDU) upgraded to Overweight from Equal Weight at Barclays with analyst Gregory Zhao saying the online marketing services and new artificial intelligence initiatives of Baidu Core are reaching an inflection point. 5. Syros Pharmaceuticals (SYRS) upgraded to Buy from Neutral at H.C. Wainwright with analyst Andrew Fein saying with the SY-1365 discontinuation behind the company, it is clear that Syros has been able to learn from what that asset provided and "make a strong decision to pursue the better of the two CDK7 inhibitors with SY-5609." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$8.42 /

+0.85 (+11.23%)

SPR Spirit AeroSystems
$19.69 /

-0.16 (-0.81%)

BIDU Baidu
$137.79 /

+3.84 (+2.87%)

AMZN Amazon.com
$3,183.43 /

+135.05 (+4.43%)

AMD AMD
$79.65 /

+3.07 (+4.01%)

AMD AMD
$79.65 /

+3.07 (+4.01%)

11/04/20 Goldman Sachs
AMD upgraded to Conviction Buy from Neutral at Goldman Sachs
10/28/20
Fly Intel: Top five analyst upgrades
10/28/20 JPMorgan
AMD price target raised to $86 from $62 at JPMorgan
10/28/20 RBC Capital
Intel price target lowered to $40 from $45 at RBC Capital
SPR Spirit AeroSystems
$19.69 /

-0.16 (-0.81%)

11/04/20 Cowen
Spirit AeroSystems upgraded to Outperform from Market Perform at Cowen
09/24/20 Wolfe Research
Spirit AeroSystems upgraded to Outperform from Peer Perform at Wolfe Research
09/10/20 Barclays
Spirit AeroSystems price target raised to $24 from $22 at Barclays
09/08/20 Morgan Stanley
Spirit AeroSystems initiated with an Underweight at Morgan Stanley
AMZN Amazon.com
$3,183.43 /

+135.05 (+4.43%)

11/04/20 BofA
California vote helps ease 'a big uncertainty' for Uber, says BofA
11/04/20 China Renaissance
Amazon.com upgraded to Buy with $4,000 target at China Renaissance
11/04/20 China Renaissance
Amazon.com upgraded to Buy from Hold at China Renaissance
11/03/20 Truist
Green Dot appears to have won flex debit work at Amazon, says Truist
BIDU Baidu
$137.79 /

+3.84 (+2.87%)

11/04/20 Barclays
Baidu upgraded to Overweight on inflection point at Barclays
11/04/20 Barclays
Baidu upgraded to Overweight from Equal Weight at Barclays
11/03/20 Loop Capital
Baidu price target raised to $150 from $130 at Loop Capital
11/02/20 Goldman Sachs
Baidu price target raised to $162 from $144 at Goldman Sachs
SYRS Syros Pharmaceuticals
$8.42 /

+0.85 (+11.23%)

11/04/20 H.C. Wainwright
Syros Pharmaceuticals upgraded to Buy from Neutral at H.C. Wainwright
10/26/20 Roth Capital
Syros Pharmaceuticals price target raised to $20 from $17 at Roth Capital
09/22/20 Alliance Global Partners
Syros Pharmaceuticals initiated with a Buy at Alliance Global Partners
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
SYRS Syros Pharmaceuticals
$8.42 /

+0.85 (+11.23%)

SPR Spirit AeroSystems
$19.69 /

-0.16 (-0.81%)

BIDU Baidu
$137.79 /

+3.84 (+2.87%)

AMZN Amazon.com
$3,183.43 /

+135.05 (+4.43%)

AMD AMD
$79.65 /

+3.07 (+4.01%)

BIDU Baidu
$137.79 /

+3.84 (+2.87%)

AMZN Amazon.com
$3,183.43 /

+135.05 (+4.43%)

AMD AMD
$79.65 /

+3.07 (+4.01%)

SPR Spirit AeroSystems
$19.69 /

-0.16 (-0.81%)

BIDU Baidu
$137.79 /

+3.84 (+2.87%)

AMZN Amazon.com
$3,183.43 /

+135.05 (+4.43%)

AMD AMD
$79.65 /

+3.07 (+4.01%)

SPR Spirit AeroSystems
$19.69 /

-0.16 (-0.81%)

BIDU Baidu
$137.79 /

+3.84 (+2.87%)

AMZN Amazon.com
$3,183.43 /

+135.05 (+4.43%)

AMD AMD
$79.65 /

+3.07 (+4.01%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.